Ari Gershon

Ari Gershon is a highly experienced professional in the fields of psychiatry and pharmacovigilance, currently serving as the Translational Innovation Lead at Clexio Biosciences since 2019, where responsibilities include identifying and evaluating drug targets for psychiatric and neurological conditions. Prior roles at Teva Pharmaceuticals involved leading safety support for neuropsychiatry products and implementing novel safety evaluation processes. With a background in clinical psychiatry and research at institutions such as Sheba - Tel Ha SHomer Hospital and Aviv Center for Mental and Behavioral Treatment, Ari has contributed significantly to schizophrenia research and served as an expert witness in forensic psychiatry. Education includes degrees from Harvard University, Cornell University, and The Rockefeller University, with a strong emphasis on biochemical sciences and developmental neurobiology.